ClinicalTrials.gg
Not yet recruitingNCT07945769BFR-AcuteRehabUpdated Nov 18, 2026

Blood Flow Restriction Training in Acute Hospital Rehabilitation

An interventional study of Passive Blood Flow Restriction - Distal Forearm and Passive Sham Blood Flow Restriction in Distal Forearm Injuries, Hand Joint Instability and Midcarpal Instability, sponsored by Paracelsus Medical University. Not yet recruiting at 1 site in Austria. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Paracelsus Medical University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Musculoskeletal injuries and conditions requiring temporary immobilization or reduced loading can lead to rapid losses of muscle mass and strength. Blood flow restriction (BFR) is a rehabilitation technique that uses an inflatable cuff placed around the proximal part of an arm or leg to temporarily restrict blood flow. The BFR-AcuteRehab study aims to investigate whether adding BFR to conventional rehabilitation improves physical function and recovery compared with sham BFR (sBFR), which uses minimal cuff pressure.

This prospective, randomized, sham-controlled clinical study will include 210 adults aged 18-60 years with unilateral musculoskeletal injuries or conditions affecting the distal upper or lower extremity. Participants will be assigned to one of three predefined clinical cohorts: (1) distal forearm injuries or conditions requiring temporary immobilization or reduced loading (n = 66); (2) hand joint instability, including midcarpal instability (n = 66); and (3) distal lower-leg injuries or conditions requiring temporary immobilization or reduced loading (n = 78).

Within each cohort, participants will be randomly assigned in a 1:1 ratio to BFR or sham BFR. All participants will receive conventional physiotherapy and/or occupational therapy in addition to their allocated intervention.

For participants with distal forearm or distal lower-leg injuries or conditions, BFR or sham BFR will be applied passively, without concomitant exercise, two to three times per week for the duration of the immobilization or load-restriction period. Participants with hand joint instability will receive active BFR or sham BFR during conventional therapeutic exercises, two to three times per week for 12 weeks.

Assessments will be conducted at baseline (T0), at the end of the respective intervention period (T1), and approximately one year after baseline (T2). The primary outcomes are upper-extremity function, assessed using the Quick Disabilities of the Arm, Shoulder and Hand questionnaire (QuickDASH) in the two upper-extremity cohorts, and lower-extremity function, assessed using the Lower Extremity Functional Scale (LEFS) in the distal lower-leg cohort.

Secondary outcomes include muscle strength, health-related quality of life, anthropometric measurements, body composition, ultrasound-derived muscle morphology, residual functional deficits, sick-leave duration, return-to-work status, and adverse events.

The study will evaluate whether BFR provides additional benefits to conventional rehabilitation in patients with musculoskeletal injuries or conditions of the distal upper and lower extremities.

Read the detailed description

Background and Rationale Musculoskeletal injuries and conditions affecting the distal upper and lower extremities frequently require temporary immobilization or reduced mechanical loading during the early stages of rehabilitation. These restrictions can result in substantial reductions in skeletal muscle mass, muscle strength, and physical function. Preserving muscle function during this period is therefore an important rehabilitation objective.

Blood flow restriction (BFR) involves applying an inflatable pneumatic cuff to the proximal portion of a limb to partially restrict arterial blood flow and limit venous return. Previous research suggests that BFR combined with low-load resistance exercise can improve muscle strength and hypertrophy while requiring lower mechanical loads than conventional resistance training. Passive BFR without concomitant exercise may also help attenuate muscle loss during immobilization. However, evidence regarding its effectiveness in patients with distal upper- and lower-extremity injuries and hand joint instability remains limited.

The BFR-AcuteRehab study will investigate whether supervised BFR interventions provide additional benefits to conventional physiotherapy and/or occupational therapy compared with sham BFR (sBFR).

Study Design and Setting This prospective, randomized, sham-controlled clinical study will be conducted at the Institute of Physical Medicine and General Rehabilitation, University Hospital Salzburg, Austria. Participants will be recruited from the Department of Orthopedic Surgery and Traumatology.

A total of 210 adults aged 18-60 years will be enrolled across three predefined clinical cohorts:

Cohort I: Distal forearm injuries or conditions requiring temporary immobilization or reduced loading (n = 66).

Cohort II: Hand joint instability, including midcarpal instability (n = 66). Cohort III: Distal lower-leg injuries or conditions requiring temporary immobilization or reduced loading (n = 78).

Following written informed consent and baseline assessments, participants will be randomized separately within each clinical cohort in a 1:1 ratio to BFR or sBFR. Computer-generated randomization sequences will use permuted blocks with randomly varying block sizes. All participants will receive conventional physiotherapy and/or occupational therapy according to their clinical condition and treatment plan.

Intervention Procedures BFR and sBFR will be administered by trained therapists using automatic pneumatic cuffs (Delfi Personalized BFR; Delfi Medical Innovations Inc., Vancouver, Canada). Cuff pressure will be determined relative to each participant's individual limb occlusion pressure (LOP).

In Cohort I, passive BFR will be applied without concomitant exercise during the immobilization or load-restriction period. Cuff pressure will be set at 50% LOP during weeks 1-2 and increased to 60% LOP from week 3 onward. Each session will consist of five 5-minute periods of cuff inflation separated by 3-minute reperfusion intervals with the cuff deflated. Sessions will be performed two to three times per week.

In Cohort II, active BFR will be applied during therapeutic exercises prescribed as part of conventional physiotherapy and/or occupational therapy. Cuff pressure will be set at 50% LOP during weeks 1-2 and increased to 60% LOP from week 3 until completion of the 12-week intervention. The cuff will remain inflated during exercise and will be deflated during rest periods of approximately 1-2 minutes between exercises. Total occlusion time will not exceed 25 minutes per session. Sessions will be performed two to three times per week.

In Cohort III, passive BFR will be applied without concomitant exercise during the immobilization or load-restriction period. Cuff pressure will be set at 70% LOP during weeks 1-2 and increased to 80% LOP from week 3 onward. Each session will consist of five 5-minute periods of occlusion separated by 3-minute reperfusion intervals with the cuff deflated. Sessions will be performed two to three times per week.

Participants allocated to sBFR will receive the corresponding cohort-specific sham intervention using the minimal applicable cuff pressure relative to the individual LOP. Session frequency, intervention duration, and cuff application procedures will follow the corresponding BFR intervention protocols.

Outcome Assessments Study assessments will be conducted at three time points: baseline (T0), immediately following the respective intervention period (T1), and approximately one year after baseline (T2).

For Cohorts I and III, T1 will correspond to the end of the immobilization or load-restriction period, according to clinical progress and medical clearance. For Cohort II, T1 will occur after completion of the 12-week intervention.

The primary outcomes will assess upper-extremity function using the Quick Disabilities of the Arm, Shoulder and Hand questionnaire (QuickDASH) in Cohorts I and II, and lower-extremity function using the Lower Extremity Functional Scale (LEFS) in Cohort III.

Secondary assessments will include muscle strength, health-related quality of life (EQ-5D-5L), anthropometric measurements, body composition by bioelectrical impedance analysis, muscle morphology by ultrasonography, residual functional deficits, sick-leave duration, and return-to-work status.

Muscle morphology will be evaluated bilaterally using B-mode ultrasound. Muscle thickness and cross-sectional area will be assessed in the upper-extremity cohorts, whereas muscle cross-sectional area will be assessed in the lower-extremity cohort. Additional muscle architecture measurements will be performed as specified in the study protocol.

Assessments requiring active loading of the affected extremity will only be performed when clinically permitted. Where applicable, measurements will be obtained bilaterally to compare the affected and contralateral extremities.

Statistical Analysis and Safety Monitoring Statistical analyses will be conducted separately for the three clinical cohorts according to the intention-to-treat principle. Repeated continuous outcomes will be analyzed using linear mixed-effects models, including treatment group, time, and the treatment-by-time interaction as fixed effects and a participant-specific random intercept.

The primary treatment comparison will assess between-group differences at T1. Comparisons at T2 will evaluate longer-term outcomes.

Adverse events and serious adverse events will be monitored from enrollment until completion of the post-intervention assessment (T1). Events will be assessed during each intervention session and documented according to the study protocol. Study interventions will be interrupted when continuation is considered clinically inappropriate.

02

Conditions studied

  • Distal Forearm Injuries
  • Hand Joint Instability
  • Midcarpal Instability
  • Distal Lower-leg Injuries

Keywords

  • Blood Flow Restriction
  • Musculoskeletal Injury
  • Immobilisation
  • Physical Function
  • Muscle Strength
  • Acute Rehabilitation
  • Midcarpal Instability
03

In context

Joint Instability

118 studies on the registry are indexed under Joint Instability; 23 are open to participants now.

This study's planned enrollment of 210 is above the median of 46 across 60 interventional studies indexed under Joint Instability.

Browse Joint Instability studies →

Lead sponsor

Paracelsus Medical University is the lead sponsor of 34 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 60 years at the time of enrollment.
  • Unilateral musculoskeletal injury or condition affecting the distal region of an upper or lower extremity and requiring temporary immobilization or reduced loading, with an anticipated duration of immobilization or load restriction of 4 to 8 weeks.
  • For upper-extremity participants: involvement of the forearm and/or hand, including fractures, tendon injuries or ruptures, tendinopathies, or functional instability, including midcarpal instability.
  • For lower-extremity participants: involvement of the lower leg and/or foot, including fractures, tendon injuries or ruptures, or tendinopathies.

Exclusion criteria

Exclusion Criteria:

  • Insufficient German language proficiency in spoken or written form.
  • Peripheral vascular disease.
  • Tumor.
  • History or presence of deep vein thrombosis or pulmonary embolism.
  • Cardiac arrhythmia or coronary heart disease.
  • Diabetes mellitus.
  • Resting blood pressure greater than 160/95 mmHg.
  • Current musculoskeletal injuries of the contralateral limb.
  • Neurological disorders affecting the contralateral limb.
  • Known or suspected pregnancy at the time of enrollment. If pregnancy status is uncertain, a pregnancy test will be performed before study inclusion.
  • Wound-healing disorders that do not allow for partial occlusion of blood flow.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Distal Forearm: BFR

    Participants with distal forearm injuries or conditions requiring temporary immobilization or reduced loading will receive conventional rehabilitation plus passive BFR without concomitant exercise. Cuff pressure will be set at 50% of limb occlusion pressure (LOP) during weeks 1-2 and 60% from week 3 until the end of immobilization or load restriction. Each session will consist of five 5-minute occlusion periods separated by 3-minute reperfusion intervals, performed 2-3 times per week.

    Other: Passive Blood Flow Restriction - Distal Forearm

  • Sham comparator
    Distal Forearm: Sham BFR

    Participants will receive conventional rehabilitation plus passive sham BFR without concomitant exercise. Cuff pressure will be set at the minimum applicable pressure relative to the individual's LOP. Each session will consist of five 5-minute periods of cuff application separated by 3-minute reperfusion intervals with the cuff deflated. Sessions will be performed 2-3 times per week throughout the immobilization or load-restriction period.

    Other: Passive Sham Blood Flow Restriction

  • Experimental
    Hand Joint Instability: BFR

    Participants with hand joint instability, including midcarpal instability, will receive conventional physiotherapy and/or occupational therapy combined with active BFR during therapeutic exercise. Cuff pressure will be set at 50% LOP during weeks 1-2 and increased to 60% LOP from week 3. The cuff will remain inflated during exercise and will be deflated during rest periods of approximately 1-2 minutes. Total occlusion time will not exceed 25 minutes per session. The intervention will be performed 2-3 times per week for 12 weeks.

    Other: Active Blood Flow Restriction - Hand Joint Instability

  • Sham comparator
    Hand Joint Instability: Sham BFR

    Participants with hand joint instability will receive conventional physiotherapy and/or occupational therapy combined with active sham BFR during therapeutic exercise. Cuff pressure will be set at the minimum applicable pressure relative to the individual's LOP. The cuff will remain inflated during exercise and will be fully deflated during rest periods of approximately 1-2 minutes. Total cuff application time will not exceed 25 minutes per session. The intervention will be performed 2-3 times per week for 12 weeks.

    Other: Active Sham Blood Flow Restriction - Hand Joint Instability

  • Experimental
    Distal Lower Leg: BFR

    Participants with distal lower-leg injuries or conditions requiring temporary immobilization or reduced loading will receive conventional rehabilitation plus passive BFR without concomitant exercise. Cuff pressure will be set at 70% LOP during weeks 1-2 and increased to 80% LOP from week 3 until the end of immobilization or load restriction. Each session will consist of five 5-minute occlusion periods separated by 3-minute reperfusion intervals, performed 2-3 times per week.

    Other: Passive Blood Flow Restriction - Distal Lower Leg

  • Sham comparator
    Distal Lower Leg: Sham BFR

    Participants will receive conventional rehabilitation plus passive sham BFR without concomitant exercise. Cuff pressure will be set at the minimum applicable pressure relative to the individual's LOP. Each session will consist of five 5-minute periods of cuff application separated by 3-minute reperfusion intervals with the cuff deflated. Sessions will be performed 2-3 times per week throughout the immobilization or load-restriction period.

    Other: Passive Sham Blood Flow Restriction - Distal Lower Leg

Interventions

  • OtherPassive Blood Flow Restriction - Distal Forearm

    Passive BFR using an automatic pneumatic cuff (Delfi Personalized BFR) applied to the proximal upper extremity without concomitant exercise. Cuff pressure will be set at 50% of individual limb occlusion pressure (LOP) during weeks 1-2 and 60% from week 3 onward. Each session will consist of five 5-minute occlusion periods separated by 3-minute reperfusion intervals with the cuff deflated. Treatment will be performed 2-3 times per week during the immobilization or load-restriction period.

  • OtherPassive Sham Blood Flow Restriction

    Passive sham BFR using an automatic pneumatic cuff applied to the proximal affected extremity without concomitant exercise. Cuff pressure will be set at the minimal applicable percentage of the individual's limb occlusion pressure (LOP). Each session will consist of five 5-minute periods of cuff application separated by 3-minute reperfusion intervals with the cuff deflated. Treatment will be performed 2-3 times per week throughout the immobilization or load-restriction period.

  • OtherActive Blood Flow Restriction - Hand Joint Instability

    Active BFR using an automatic pneumatic cuff during therapeutic exercises prescribed as part of conventional physiotherapy and/or occupational therapy. Cuff pressure will be set at 50% LOP during weeks 1-2 and increased to 60% from week 3. The cuff will remain inflated during exercise and deflated during rest periods of approximately 1-2 minutes between exercises. Total occlusion time will not exceed 25 minutes per session. Treatment will be performed 2-3 times per week for 12 weeks.

  • OtherActive Sham Blood Flow Restriction - Hand Joint Instability

    Active sham BFR using an automatic pneumatic cuff during therapeutic exercises prescribed as part of conventional physiotherapy and/or occupational therapy. Cuff pressure will be set at the minimal applicable percentage of the individual's limb occlusion pressure (LOP). The cuff will remain inflated during exercise and fully deflated during rest periods of approximately 1-2 minutes between exercises. Total cuff application time will not exceed 25 minutes per session. Treatment will be performed 2-3 times per week for 12 weeks.

  • OtherPassive Blood Flow Restriction - Distal Lower Leg

    Passive BFR using an automatic pneumatic cuff (Delfi Personalized BFR) applied to the proximal lower extremity without concomitant exercise. Cuff pressure will be set at 70% LOP during weeks 1-2 and increased to 80% from week 3 onward. Each session will consist of five 5-minute occlusion periods separated by 3-minute reperfusion intervals with the cuff deflated. Treatment will be performed 2-3 times per week during the immobilization or load-restriction period.

  • OtherPassive Sham Blood Flow Restriction - Distal Lower Leg

    Passive sham BFR using an automatic pneumatic cuff (Delfi Personalized BFR) applied to the proximal affected lower extremity without concomitant exercise. Cuff pressure will be set at the minimal applicable percentage of the individual's limb occlusion pressure (LOP). Each session will consist of five 5-minute periods of cuff application separated by 3-minute reperfusion intervals with the cuff fully deflated. Treatment will be performed 2-3 times per week throughout the immobilization or load-restriction period.

06

What researchers measure

Primary outcomes

  1. Upper-Extremity Function (QuickDASH) - Distal Forearm Cohort

    Upper-extremity function will be assessed using the Quick Disabilities of the Arm, Shoulder and Hand questionnaire (QuickDASH), an 11-item patient-reported outcome measure assessing physical function and symptoms. Scores range from 0 to 100, with higher scores indicating greater disability. The primary treatment comparison between BFR and sham BFR will be performed at T1. T2 will provide a longer-term follow-up comparison.

    Time frame: Baseline (T0), end of immobilization or load-restriction period (T1; approximately 4-8 weeks), and follow-up (T2; approximately 1 year after baseline)

  2. Upper-Extremity Function (QuickDASH) - Hand Joint Instability Cohort

    Upper-extremity function will be assessed using the Quick Disabilities of the Arm, Shoulder and Hand questionnaire (QuickDASH), an 11-item patient-reported outcome measure assessing physical function and symptoms. Scores range from 0 to 100, with higher scores indicating greater disability. The primary treatment comparison between BFR and sham BFR will be performed at T1, after completion of the 12-week intervention. T2 will provide a longer-term follow-up comparison.

    Time frame: Baseline (T0), post-intervention at 12 weeks (T1), and follow-up (T2; approximately 1 year after baseline)

  3. Lower-Extremity Function (LEFS) - Distal Lower-Leg Cohort

    Lower-extremity function will be assessed using the Lower Extremity Functional Scale (LEFS), a 20-item patient-reported questionnaire evaluating difficulties in performing everyday and physical activities. Scores range from 0 to 80, with higher scores indicating better lower-extremity function. The primary treatment comparison between BFR and sham BFR will be performed at T1. T2 will provide a longer-term follow-up comparison.

    Time frame: Baseline (T0), end of immobilization or load-restriction period (T1; approximately 4-8 weeks), and follow-up (T2; approximately 1 year after baseline).

Secondary outcomes

  1. Handgrip Strength (kgf) - Upper-Extremity Cohorts

    Handgrip strength will be assessed bilaterally using a hydraulic hand dynamometer (SAEHAN H5001). Participants will be seated with the shoulder adducted and neutrally rotated, elbow flexed at 90 degrees, forearm neutral, and wrist in slight extension. Following familiarization, three maximal voluntary contractions of 5 seconds each will be performed per hand. The highest value obtained, expressed in kilograms of force (kgf), will be recorded for analysis. Testing of the affected extremity will only be performed when clinically permitted.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for distal forearm or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline).

  2. Maximal Pain-Free Isometric Muscle Strength (Nm) - Lower-Extremity Cohort

    Maximal pain-free isometric muscle strength will be assessed bilaterally using an isokinetic dynamometer (Biodex System 4 Pro) operated in isometric mode. Knee extensor strength will be assessed at 90 degrees of knee flexion. Ankle plantarflexion and dorsiflexion strength will be assessed at standardized joint positions. Following familiarization and submaximal practice contractions, three maximal voluntary isometric contractions will be performed for each movement. Peak torque for each movement, expressed in Newton-meters (Nm), will be recorded for analysis. Testing of the affected extremity will only be performed when clinically permitted.

    Time frame: Baseline (T0), end of immobilization or load-restriction period (T1: approximately 4-8 weeks), and follow-up (T2: approximately 1 year after baseline).

  3. Health-Related Quality of Life (EQ-5D-5L)

    Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The instrument evaluates five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on five response levels, ranging from no problems to extreme problems. Responses will describe the participant's health status across the five dimensions. The questionnaire will be administered to participants in all three clinical cohorts.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for distal forearm and lower-leg cohorts or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline).

  4. Body Mass (kg)

    Body mass will be measured using a calibrated digital scale (LAICA), with participants wearing light clothing and no shoes. Measurements will be performed following standardized anthropometric procedures. Body mass will be recorded in kilograms (kg). Assessments will be performed in all three clinical cohorts.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for distal forearm and lower-leg cohorts or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline).

  5. Body Height (cm)

    Standing height will be measured without shoes using a custom-made stadiometer, with participants standing upright in a standardized position. Measurements will be performed according to standardized anthropometric procedures and recorded in centimeters (cm). Standing height will be assessed at baseline only in all three clinical cohorts.

    Time frame: Baseline (T0), before randomization and initiation of the intervention.

  6. Body Mass Index (BMI, kg/m²)

    Body mass index (BMI) will be calculated as body mass in kilograms divided by standing height in meters squared (kg/m²). Body mass will be measured at each scheduled assessment, while standing height will be measured at baseline (T0). BMI will be calculated for participants in all three clinical cohorts.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for distal forearm and lower-leg cohorts or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline).

  7. Phase Angle (degrees) Assessed by Bioelectrical Impedance Analysis

    Phase angle will be assessed using bioelectrical impedance analysis (BIA) under standardized measurement conditions. Assessments will be performed with attention to measurement timing, hydration status, recent food and fluid intake, physical activity, body position, and electrode placement. Phase angle will be recorded in degrees (°) for participants in all three clinical cohorts.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for distal forearm and lower-leg cohorts, or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline).

  8. Body Fat Mass (kg) Assessed by Bioelectrical Impedance Analysis

    Absolute body fat mass will be assessed using bioelectrical impedance analysis (BIA) under standardized measurement conditions. Measurements will be performed under comparable conditions at each assessment, considering hydration status, recent food and fluid intake, physical activity, body position, and electrode placement. Body fat mass will be recorded in kilograms (kg) for participants in all three clinical cohorts.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for distal forearm and lower-leg cohorts, or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline).

  9. Body Fat Percentage (%) Assessed by Bioelectrical Impedance Analysis

    Relative body fat mass will be assessed using bioelectrical impedance analysis (BIA) under standardized measurement conditions. Body fat percentage represents the estimated proportion of total body mass consisting of fat tissue and will be expressed as a percentage (%). Assessments will be performed under comparable conditions at each time point for participants in all three clinical cohorts.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for distal forearm and lower-leg cohorts, or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline).

  10. Fat-Free Mass (kg) Assessed by Bioelectrical Impedance Analysis

    Absolute fat-free mass will be assessed using bioelectrical impedance analysis (BIA) under standardized measurement conditions. Fat-free mass represents the estimated mass of body components excluding fat. Measurements will be performed under comparable conditions at each assessment, considering hydration status, recent food and fluid intake, physical activity, body position, and electrode placement. Results will be recorded in kilograms (kg) for participants in all three clinical cohorts.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for distal forearm and lower-leg cohorts, or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline).

  11. Fat-Free Mass Percentage (%) Assessed by Bioelectrical Impedance Analysis

    Relative fat-free mass will be assessed using bioelectrical impedance analysis (BIA) under standardized measurement conditions. Fat-free mass percentage represents the estimated proportion of total body mass consisting of fat-free components and will be expressed as a percentage (%). Assessments will be performed under comparable conditions at each time point for participants in all three clinical cohorts.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for distal forearm and lower-leg cohorts, or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline).

  12. Body Cell Mass (kg) Assessed by Bioelectrical Impedance Analysis

    Body cell mass (BCM) will be estimated using bioelectrical impedance analysis (BIA) under standardized measurement conditions. BCM represents the estimated mass of metabolically active body cells. Assessments will be performed under comparable conditions at each time point, considering hydration status, recent food and fluid intake, physical activity, body position, and electrode placement. Results will be recorded in kilograms (kg) for participants in all three clinical cohorts.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for distal forearm and lower-leg cohorts, or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline).

  13. Biceps Brachii Muscle Thickness by B-Mode Ultrasound

    Muscle thickness (MT) of the biceps brachii will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse ultrasound images will be obtained at 50% of the distance between the anterior aspect of the acromion and the antecubital fossa, with the arm relaxed in a neutral position. Standardized anatomical landmarks, patient positioning, and imaging settings will be maintained across assessments.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for the distal forearm cohort or 12 weeks for the hand joint instability cohort), and follow-up (T2: approximately 1 year after baseline).

  14. Biceps Brachii Muscle Cross-Sectional Area by B-Mode Ultrasound

    Anatomical cross-sectional area (CSA) of the biceps brachii will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be obtained at 50% of the distance between the anterior aspect of the acromion and the antecubital fossa, with the arm relaxed in a neutral position. Extended-field-of-view or panoramic imaging will be used when required.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for the distal forearm cohort or 12 weeks for the hand joint instability cohort), and follow-up (T2: approximately 1 year after baseline).

  15. Triceps Brachii Muscle Thickness by B-Mode Ultrasound

    Muscle thickness (MT) of the triceps brachii will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be obtained at the standardized upper-arm site between the acromion and olecranon, with the examined musculature relaxed. Patient positioning, anatomical landmarks, and imaging settings will be standardized across assessments.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for the distal forearm cohort or 12 weeks for the hand joint instability cohort), and follow-up (T2: approximately 1 year after baseline).

  16. Triceps Brachii Muscle Cross-Sectional Area by B-Mode Ultrasound

    Anatomical cross-sectional area (CSA) of the triceps brachii will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be acquired at the standardized upper-arm site between the acromion and olecranon, with the examined muscles relaxed. Extended-field-of-view or panoramic imaging will be used when required.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for the distal forearm cohort or 12 weeks for the hand joint instability cohort), and follow-up (T2: approximately 1 year after baseline).

  17. Forearm Flexor Muscle Thickness by B-Mode Ultrasound

    Muscle thickness (MT) of the forearm flexor musculature will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be obtained over the anterior forearm compartment at the proximal 30% of the distance from the antecubital fossa toward the ulnar styloid process, measured distally from the elbow. The forearm will be relaxed in a neutral position.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for the distal forearm cohort or 12 weeks for the hand joint instability cohort), and follow-up (T2: approximately 1 year after baseline).

  18. Forearm Flexor Muscle Cross-Sectional Area by B-Mode Ultrasound

    Anatomical cross-sectional area (CSA) of the forearm flexor musculature will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be obtained over the anterior forearm compartment at the proximal 30% of the distance from the antecubital fossa toward the ulnar styloid process, with the forearm relaxed in a neutral position. Extended-field-of-view imaging will be used when required.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for the distal forearm cohort or 12 weeks for the hand joint instability cohort), and follow-up (T2: approximately 1 year after baseline).

  19. Forearm Extensor Muscle Thickness by B-Mode Ultrasound

    Muscle thickness (MT) of the forearm extensor musculature will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be obtained over the posterior/lateral forearm compartment at the proximal 30% of the distance from the antecubital fossa toward the ulnar styloid process, with the forearm relaxed in a neutral position.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for the distal forearm cohort or 12 weeks for the hand joint instability cohort), and follow-up (T2: approximately 1 year after baseline).

  20. Forearm Extensor Muscle Cross-Sectional Area by B-Mode Ultrasound

    Anatomical cross-sectional area (CSA) of the forearm extensor musculature will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be obtained over the posterior/lateral forearm compartment at the proximal 30% of the distance from the antecubital fossa toward the ulnar styloid process, with the forearm relaxed in a neutral position. Extended-field-of-view imaging will be used when required.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for the distal forearm cohort or 12 weeks for the hand joint instability cohort), and follow-up (T2: approximately 1 year after baseline).

  21. Rectus Femoris Muscle Cross-Sectional Area by B-Mode Ultrasound

    Anatomical cross-sectional area (CSA) of the rectus femoris will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be obtained at 50% of the distance between the greater trochanter and proximal border of the patella, with the participant supine and the lower extremity relaxed. Standardized anatomical landmarks and imaging settings will be used.

    Time frame: Baseline (T0), end of immobilization or load restriction (T1: approximately 4-8 weeks), and follow-up (T2: approximately 1 year after baseline).

  22. Vastus Medialis Muscle Cross-Sectional Area by B-Mode Ultrasound

    Anatomical cross-sectional area (CSA) of the vastus medialis will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be obtained at 50% of the distance between the greater trochanter and proximal border of the patella, with the participant supine and the lower extremity relaxed. Standardized anatomical landmarks and imaging settings will be used.

    Time frame: Baseline (T0), end of immobilization or load restriction (T1: approximately 4-8 weeks), and follow-up (T2: approximately 1 year after baseline).

  23. Vastus Lateralis Muscle Cross-Sectional Area by B-Mode Ultrasound

    Anatomical cross-sectional area (CSA) of the vastus lateralis will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be obtained at 50% of the distance between the greater trochanter and proximal border of the patella, with the participant supine and the lower extremity relaxed. Standardized anatomical landmarks and imaging settings will be used.

    Time frame: Baseline (T0), end of immobilization or load restriction (T1: approximately 4-8 weeks), and follow-up (T2: approximately 1 year after baseline).

  24. Medial Gastrocnemius Muscle Cross-Sectional Area by B-Mode Ultrasound

    Anatomical cross-sectional area (CSA) of the medial gastrocnemius will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be obtained at the standardized medial calf site corresponding to the proximal 30% of lower-leg length, using anatomical landmarks. The calf musculature will be relaxed during assessment.

    Time frame: Baseline (T0), end of immobilization or load restriction (T1: approximately 4-8 weeks), and follow-up (T2: approximately 1 year after baseline).

  25. Lateral Gastrocnemius Muscle Cross-Sectional Area by B-Mode Ultrasound

    Anatomical cross-sectional area (CSA) of the lateral gastrocnemius will be assessed bilaterally using B-mode ultrasonography (Aplio me, Canon Medical Systems). Transverse images will be obtained at 30% of the distance between the lateral knee joint line and lateral malleolus, measured distally from the knee. The calf musculature will be relaxed during assessment.

    Time frame: Baseline (T0), end of immobilization or load restriction (T1: approximately 4-8 weeks), and follow-up (T2: approximately 1 year after baseline).

  26. Lower-Extremity Muscle Fascicle Length by Ultrasound

    Muscle fascicle length will be assessed from longitudinal ultrasound images of the lower-extremity musculature. Fascicle length is defined as the distance along a fascicle between its insertions into the superficial and deep aponeuroses when the complete fascicle is visible. A predefined validated estimation method may be used where technically appropriate; otherwise the measurement will be recorded as unavailable.

    Time frame: Baseline (T0), end of immobilization or load restriction (T1: approximately 4-8 weeks), and follow-up (T2: approximately 1 year after baseline).

  27. Lower-Extremity Muscle Pennation Angle by Ultrasound

    Muscle pennation angle will be assessed from longitudinal ultrasound images of the lower-extremity musculature. Pennation angle is defined as the angle between the muscle fascicle and its corresponding deep aponeurosis. The same probe position, orientation, and anatomical landmarks will be reproduced at each assessment time point.

    Time frame: Baseline (T0), end of immobilization or load restriction (T1: approximately 4-8 weeks), and follow-up (T2: approximately 1 year after baseline).

  28. Handgrip Strength Limb Symmetry Index (Percent) - Upper-Extremity Cohorts

    Residual functional deficit will be assessed by comparing maximal handgrip strength of the affected and contralateral upper extremities. The limb symmetry index (LSI) will be calculated as affected-limb handgrip strength divided by contralateral-limb handgrip strength, multiplied by 100, and expressed as a percentage. A value of 100% indicates equal strength between limbs. Measurements of the affected extremity will only be performed when unrestricted use is clinically permitted.

    Time frame: Baseline (T0), post-intervention (T1: approximately 4-8 weeks for distal forearm or lower-leg cohorts, or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline). Assessments of the affected extremity will be perform

  29. Knee Extension Strength Limb Symmetry Index (Percent) - Lower-Extremity Cohort

    Residual functional deficit in knee extension strength will be assessed by comparing maximal pain-free isometric knee extensor peak torque of the affected and contralateral extremities, measured using a Biodex System 4 Pro dynamometer. The limb symmetry index (LSI) will be calculated as affected-limb peak torque divided by contralateral-limb peak torque, multiplied by 100. Results will be expressed as a percentage, with 100% indicating equal strength.

    Time frame: Baseline (T0), end of immobilization or load restriction (T1: approximately 4-8 weeks), and follow-up (T2: approximately 1 year after baseline). Affected-limb testing will be performed only when clinically permitted.

  30. Ankle Plantarflexion Strength Limb Symmetry Index (Percent) - Lower-Extremity Cohort

    Residual functional deficit in ankle plantarflexion strength will be assessed by comparing maximal pain-free isometric plantarflexion peak torque of the affected and contralateral extremities, measured using a Biodex System 4 Pro dynamometer. The limb symmetry index (LSI) will be calculated as affected-limb peak torque divided by contralateral-limb peak torque, multiplied by 100. Results will be expressed as a percentage, with 100% indicating equal strength.

    Time frame: Baseline (T0), end of immobilization or load restriction (T1: approximately 4-8 weeks), and follow-up (T2: approximately 1 year after baseline). Affected-limb testing will be performed only when clinically permitted.

  31. Ankle Dorsiflexion Strength Limb Symmetry Index (Percent) - Lower-Extremity Cohort

    Residual functional deficit in ankle dorsiflexion strength will be assessed by comparing maximal pain-free isometric dorsiflexion peak torque of the affected and contralateral extremities, measured using a Biodex System 4 Pro dynamometer. The limb symmetry index (LSI) will be calculated as affected-limb peak torque divided by contralateral-limb peak torque, multiplied by 100. Results will be expressed as a percentage, with 100% indicating equal strength.

    Time frame: Baseline (T0), end of immobilization or load restriction (T1: approximately 4-8 weeks), and follow-up (T2: approximately 1 year after baseline). Affected-limb testing will be performed only when clinically permitted.

  32. Cumulative Sick-Leave Duration (Days)

    Among participants employed at the time of injury, work absence attributable to the index musculoskeletal injury or condition will be recorded as the cumulative number of sick-leave days during the study period. Sick-leave duration will be expressed in days and evaluated separately within each clinical cohort.

    Time frame: From baseline (T0) to post-intervention (T1: approximately 4-8 weeks for distal forearm and lower-leg cohorts or 12 weeks for hand joint instability) and follow-up (T2: approximately 1 year after baseline).

  33. Number of Participants by Return-to-Work Status

    Among participants employed at the time of injury, return-to-work status will be documented at follow-up assessments and classified into three categories: (1) not returned to work; (2) returned with modified duties or reduced working hours; and (3) returned to usual work without restrictions. The number of participants in each category will be reported. Where available, the date of return to work will also be recorded.

    Time frame: Post-intervention (T1: approximately 4-8 weeks for distal forearm and lower-leg cohorts or 12 weeks for hand joint instability), and follow-up (T2: approximately 1 year after baseline).

07

Study locations

1 site
  • Institute of Physical Medicine and General Rehabilitation, University Hospital Salzburg (SALK)
    Salzburg, State of Salzburg 5020, Austria
    • Giorjines Boppre, Dr. · Contactgiorjines.boppre@pmu.ac.at · +43 5 7255 54363
    • Christoph Schulze, Univ.-Prof. Dr. med. habil. · Contactc.schulze@salk.at · +43 5 7255 53188
    • Christoph Schulze, Univ.-Prof. Dr. med. habil. · Principal investigator
    • Giorjines Boppre, Dr. · Sub investigator
    • Florian Rieder, Priv.-Doz. Dr. rer. nat. · Sub investigator
08

References and documents

Publications

  • Larsen P, Platzer OJ, Lollesgaard L, Pedersen SK, Nielsen PK, Rathleff MS, Bandholm T, Jensen ST, Elsoe R. Blood-flow restricted exercise following ankle fractures - A feasibility study. Foot Ankle Surg. 2022 Aug;28(6):726-731. doi: 10.1016/j.fas.2021.08.010. Epub 2021 Sep 14. PubMed 34531157 ↗
  • Cancio JM, Sgromolo NM, Rhee PC. Blood Flow Restriction Therapy after Closed Treatment of Distal Radius Fractures. J Wrist Surg. 2019 Aug;8(4):288-294. doi: 10.1055/s-0039-1685455. Epub 2019 Apr 16. PubMed 31404177 ↗
  • Patterson SD, Hughes L, Warmington S, Burr J, Scott BR, Owens J, Abe T, Nielsen JL, Libardi CA, Laurentino G, Neto GR, Brandner C, Martin-Hernandez J, Loenneke J. Blood Flow Restriction Exercise: Considerations of Methodology, Application, and Safety. Front Physiol. 2019 May 15;10:533. doi: 10.3389/fphys.2019.00533. eCollection 2019. PubMed 31156448 ↗
  • Hughes L, Paton B, Rosenblatt B, Gissane C, Patterson SD. Blood flow restriction training in clinical musculoskeletal rehabilitation: a systematic review and meta-analysis. Br J Sports Med. 2017 Jul;51(13):1003-1011. doi: 10.1136/bjsports-2016-097071. Epub 2017 Mar 4. PubMed 28259850 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with external researchers under the current data-sharing plan. Participant data will be pseudonymized and processed in accordance with the General Data Protection Regulation (GDPR) and applicable national data protection requirements. Access to identifiable participant information will be restricted to authorized study personnel. Study findings will be disseminated through peer-reviewed scientific publications and presentations at scientific conferences, without disclosing information that could identify individual participants.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2030, 47 months later.

Of 37 non-industry interventional studies with no phase under Joint Instability, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 37. This study's planned 47 months is above that.

Counting every sponsor, half of 42 studies reached it within 15 months; a quarter within 7 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Jan 2027
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945769
Lead sponsor
Paracelsus Medical University
Responsible party
Florian Rieder (Priv. -Doz. Dr., Paracelsus Medical University) — Principal investigator
First posted
Nov 18, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Giorjines Boppre, Dr.
Contact
giorjines.boppre@pmu.ac.at
+43 5 7255 54363
Christoph Schulze, Univ.-Prof. Dr. med. habil.
Contact
c.schulze@salk.at
+43 5 7255 53188
Christoph Schulze, Univ.-Prof. Dr. med. habil.
principal investigator · Institute of Physical Medicine and General Rehabilitation, Paracelsus Medical University Salzburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion